A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age30-75
SponsorZhejiang University
About this trial
Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Eligibility criteria
Qualifiers
Patients with BCMA positive relapsed/refractory MM;
Relapsed after hematopoietic stem cell transplantation;
Cases with recurrent positive minimal residual disease;
Extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy.
Disqualifiers
History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
Pregnant (or lactating) women;
Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
Trial design
Treatments tested in this trial
- BCMA Targeted CAR T-cells
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhejiang University
Lead sponsor
Yake Biotechnology Ltd.
Collaborator
Source ClinicalTrials.gov